Irina Velikyan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Irina Velikyan has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Bengt Långström
Department of Biochemistry and Organic Chemistry, Box 576, Husargatan 3, BMC, S-751 23 Uppsala, Sweden
2 shared publications Mats Bergström
Department of Pharmaceutical Biosciences, Uppsala University, Uppsala Biomedical Centre, Uppsala, Sweden
2 shared publications- Anders Sundin
Department of Surgical Sciences, Radiology and Molecular Imaging Uppsala University Uppsala Sweden
1 shared publication Anders Wennborg
1 shared publication- Anne Roivainen
University of Turku and Turku University Hospital
1 shared publication Barbro Eriksson
Department of Endocrine Oncology, Uppsala University Hospital, SE-751 85 Uppsala, Sweden
1 shared publication
Latest Publications
- 29 November 2016
- Published by Bioscientifica in Endocrine Abstracts
Theranostics at its best: clinical breast cancer imaging and quantification targeting HER2 receptors
The currently best known example of a commercialized theranostics is the combination of HercepTest and Herceptin wherein the former is used for HER2 expression assessment and selection of patients that might benefit from the treatment with the latter. However, HercepTest requires biopsy which is an invasive procedure, not sufficiently accurate, and very difficult to perform on several lesions and repeatedly in order to monitor the treatment response. While positron emission tomography (PET) in combination with HER2 targeting radiopharmaceutical provides quantitative whole body examination which accuracy is high and independent on heterogeneity of receptor expression. PET imaging agent, [68Ga]Ga-ABY-025, was produced in compliance with GMP and GRPP in two peptide doses. The peptide Affibody molecule, ABY-025, was provided by Affibody AB. 68Ga was obtained from a 68Ge/68Ga-generator (IGG100, Eckert & Ziegler). Patients with diagnosed metastatic breast cancer were enrolled. Two PET/CT examinations with low and high peptide content radiopharmaceuticals were performed for each patient. The examination started with dynamic acquisition (0–45 min) followed by three static runs at 1, 2 and 4 h post injection. Immunohistochemistry (IHC) on the metastasis biopsies were performed for HER2 expression verification. The study was approved by the Swedish Medical Products Agency (EudraCT 2012-005228-14, NCT01858116) and the Regional Board of Medical Ethics. The examination using radiopharmaceutical with high peptide content resulted in higher contrast images with lower uptake in healthy organs such as liver. The contrast increased with the time however already 2 h post injection was found optimum for routine use. SUVs correlated with IHC HER2-scores. Based on [68Ga]Ga-ABY-025/PET-CT, the treatment was changed in 19% of the patients. [68Ga]Ga-ABY-025/PET-CT demonstrated strong potential to improve patient management efficacy by providing pre-therapeutic accurate whole body determination of HER2 expression extent and treatment response monitoring with minimal patient discomfort.
- 29 November 2016
- Published by Bioscientifica in Endocrine Abstracts
Theranostics at its best: clinical breast cancer imaging and quantification targeting HER2 receptors
The currently best known example of a commercialized theranostics is the combination of HercepTest and Herceptin wherein the former is used for HER2 expression assessment and selection of patients that might benefit from the treatment with the latter. However, HercepTest requires biopsy which is an invasive procedure, not sufficiently accurate, and very difficult to perform on several lesions and repeatedly in order to monitor the treatment response. While positron emission tomography (PET) in combination with HER2 targeting radiopharmaceutical provides quantitative whole body examination which accuracy is high and independent on heterogeneity of receptor expression. PET imaging agent, [68Ga]Ga-ABY-025, was produced in compliance with GMP and GRPP in two peptide doses. The peptide Affibody molecule, ABY-025, was provided by Affibody AB. 68Ga was obtained from a 68Ge/68Ga-generator (IGG100, Eckert & Ziegler). Patients with diagnosed metastatic breast cancer were enrolled. Two PET/CT examinations with low and high peptide content radiopharmaceuticals were performed for each patient. The examination started with dynamic acquisition (0–45 min) followed by three static runs at 1, 2 and 4 h post injection. Immunohistochemistry (IHC) on the metastasis biopsies were performed for HER2 expression verification. The study was approved by the Swedish Medical Products Agency (EudraCT 2012-005228-14, NCT01858116) and the Regional Board of Medical Ethics. The examination using radiopharmaceutical with high peptide content resulted in higher contrast images with lower uptake in healthy organs such as liver. The contrast increased with the time however already 2 h post injection was found optimum for routine use. SUVs correlated with IHC HER2-scores. Based on [68Ga]Ga-ABY-025/PET-CT, the treatment was changed in 19% of the patients. [68Ga]Ga-ABY-025/PET-CT demonstrated strong potential to improve patient management efficacy by providing pre-therapeutic accurate whole body determination of HER2 expression extent and treatment response monitoring with minimal patient discomfort.
- 31 August 2010
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 37 (6) , 724
Imaging biomarkers for diagnosis and quantification with positron emission tomography: assistance to therapy
- 31 August 2010
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 37 (6) , 724
Imaging biomarkers for diagnosis and quantification with positron emission tomography: assistance to therapy
- 1 February 2004
- Vol. 45 (2) , 347-55
68Ga-labeled oligonucleotides for in vivo imaging with PET.
The biologic evaluation in living rats of (68)Ga-labeled oligonucleotides as imaging agents for PET is reported. (68)Ga, a positron-emitting radionuclide (half-life, 68 min), along with a macrocyclic chelating agent, 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA), was used for labeling of antisense oligonucleotides targeting activated human K-ras oncogene. The biologic properties of 3 different forms of the oligonucleotides-that is, 2'-deoxyphosphodiester (PO), 2'-deoxyphosphorothioate (PS), and 2'-O-methyl phosphodiester (OMe)-were studied first. The biodistribution and biokinetics were evaluated in vivo in athymic rats, each bearing a tumor of A549 cells, containing K-ras point mutation in codon 12, and a tumor of BxPC-3 cells, containing wild-type K-ras. Dynamic PET imaging lasting up to 2 h was performed immediately after intravenous injection of (68)Ga-oligonucleotide. Blank studies were performed using (68)GaCl(3) or (68)Ga-DOTA alone without oligonucleotide. The (68)Ga-antisense oligonucleotide uptake in tumors was also compared with the (18)F-FDG and (68)Ga-sense oligonucleotide uptakes. In addition, oligonucleotide binding to human plasma proteins and to human albumin was examined by means of ultrafiltration. The oligonucleotides can be stably labeled with (68)Ga and DOTA chelate. Intravenously injected (68)Ga-oligonucleotides of 17-mer length revealed high-quality PET images, allowing quantification of the biokinetics in major organs and in tumors. The biodistribution and biokinetics of intravenously administered (68)Ga-oligonucleotide varied considerably with the nature of the oligonucleotide backbone. We conclude that (68)Ga labeling of oligonucleotides is a convenient approach for in vivo imaging and quantification of oligonucleotide biokinetics in living animals with PET.
- 1 February 2004
- Vol. 45 (2) , 347-55
68Ga-labeled oligonucleotides for in vivo imaging with PET.
The biologic evaluation in living rats of (68)Ga-labeled oligonucleotides as imaging agents for PET is reported. (68)Ga, a positron-emitting radionuclide (half-life, 68 min), along with a macrocyclic chelating agent, 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA), was used for labeling of antisense oligonucleotides targeting activated human K-ras oncogene. The biologic properties of 3 different forms of the oligonucleotides-that is, 2'-deoxyphosphodiester (PO), 2'-deoxyphosphorothioate (PS), and 2'-O-methyl phosphodiester (OMe)-were studied first. The biodistribution and biokinetics were evaluated in vivo in athymic rats, each bearing a tumor of A549 cells, containing K-ras point mutation in codon 12, and a tumor of BxPC-3 cells, containing wild-type K-ras. Dynamic PET imaging lasting up to 2 h was performed immediately after intravenous injection of (68)Ga-oligonucleotide. Blank studies were performed using (68)GaCl(3) or (68)Ga-DOTA alone without oligonucleotide. The (68)Ga-antisense oligonucleotide uptake in tumors was also compared with the (18)F-FDG and (68)Ga-sense oligonucleotide uptakes. In addition, oligonucleotide binding to human plasma proteins and to human albumin was examined by means of ultrafiltration. The oligonucleotides can be stably labeled with (68)Ga and DOTA chelate. Intravenously injected (68)Ga-oligonucleotides of 17-mer length revealed high-quality PET images, allowing quantification of the biokinetics in major organs and in tumors. The biodistribution and biokinetics of intravenously administered (68)Ga-oligonucleotide varied considerably with the nature of the oligonucleotide backbone. We conclude that (68)Ga labeling of oligonucleotides is a convenient approach for in vivo imaging and quantification of oligonucleotide biokinetics in living animals with PET.